BFA
CASC

BlackRock Fund Advisors’s Cascadian Therapeutics, Inc. CASC Stock Holding History

BlackRock Fund Advisors’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$200K Sell
46,366
-295,269
-86% -$1.91M ﹤0.01% 3426
2016
Q3 		$3.36M Buy
341,635
+96,278
+39% +$683K ﹤0.01% 3032
2016
Q2 		$1.39M Sell
245,357
-364,736
-60% -$2.48M ﹤0.01% 3235
2016
Q1 		$4.65M Sell
610,093
-2,747
-0.4% -$21.2K ﹤0.01% 2781
2015
Q4 		$8.16M Buy
612,840
+202,331
+49% +$3.48M ﹤0.01% 2564
2015
Q3 		$6.75M Sell
410,509
-27,013
-6% -$554K ﹤0.01% 2606
2015
Q2 		$9.82M Buy
437,522
+2,093
+0.5% +$33.1K ﹤0.01% 2510
2015
Q1 		$4.26M Buy
435,429
+61,388
+16% +$602K ﹤0.01% 2920
2014
Q4 		$4.26M Buy
374,041
+52,120
+16% +$566K ﹤0.01% 2963
2014
Q3 		$3.71M Buy
321,921
+26,763
+9% +$409K ﹤0.01% 2917
2014
Q2 		$5.74M Buy
295,158
+260,270
+746% +$4.59M ﹤0.01% 2760
2014
Q1 		$626K Buy
34,888
+6,574
+23% +$108K ﹤0.01% 3231
2013
Q4 		$299K Sell
28,314
-115,222
-80% -$1.29M ﹤0.01% 3320
2013
Q3 		$1.77M Buy
143,536
+34,223
+31% +$360K ﹤0.01% 3139
2013
Q2 		$1.03M Buy
+109,313
New +$1.4M ﹤0.01% 3154

Other funds holding CASC

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SH
Sandia Holdings Greenwich, Connecticut $213M AUM 29.35% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

BlackRock Fund Advisors's CASC Position: Q4 2016 in Review

BlackRock Fund Advisors reduced its Cascadian Therapeutics, Inc. (CASC) stake by 86% in Q4 2016, selling an estimated $1.91M and leaving 46,366 shares worth $200K. The position accounts for ﹤0.01% of the portfolio, ranked #3426.

BlackRock Fund Advisors first reported a position in CASC in Q2 2013 and has held it in 15 quarters since. The position peaked at $9.82M in Q2 2015. 57 funds tracked by Wall St. Rank hold CASC as of Q4 2016.

  • BlackRock Fund Advisors held 46,366 shares of Cascadian Therapeutics, Inc. worth $200K as of Q4 2016.
  • BlackRock Fund Advisors sold 295,269 Cascadian Therapeutics, Inc. shares in Q4 2016, an estimated $1.91M.
  • Cascadian Therapeutics, Inc. made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3426 holding.
  • BlackRock Fund Advisors first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Fund Advisors's Cascadian Therapeutics, Inc. position peaked at $9.82M in Q2 2015.
  • 57 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.